News

First antibody-drug conjugate for multiple myeloma patients with limited treatment options

First antibody-drug conjugate for multiple myeloma patients with limited treatment options

 

Published: 24 Jul 2020

EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation in the European Union for Blenrep (belantamab mafodotin) to treat adult patients with relapsed and refractory multiple myeloma who no longer respond to treatment with an immunomodulatory agent, a proteasome inhibitor and a CD-38 monoclonal antibody.

Multiple myeloma is a cancer of a type of white blood cell called plasma cells that is responsible for about 2% of all cancer deaths. Normal plasma cells are found in the bone marrow and are an important part of the immune system. Plasma cells make the antibodies that enable the body to recognise and attack germs such as viruses or bacteria. They originate from B-cell lymphocytes and form when B-cells respond to an infection. When plasma cells become cancerous, they no longer protect the body from infections and produce abnormal proteins that can cause problems affecting the kidneys, bones or blood.

Source: www.ema.europa.eu

Jul 27, 2020 15:25
Number of visit : 105

Comments

Sender name is required
Email is required
Characters left: 500
Comment is required

نقشه
No:13, 4th Golbarg East , Fakhar Moghadam St. Dadman Blv , Shahrak-e Gharb ,Tehran, Iran
Tel: 021 88368521-3
Fax: 021 88368520
Email : info@shafadarou.org